Literature DB >> 11973420

Intravenous adrenomedullin in myocardial function and energy metabolism in patients after myocardial infarction.

Noritoshi Nagaya1, Yoichi Goto, Toru Satoh, Hitoshi Sumida, Sunao Kojima, Kunio Miyatake, Kenji Kangawa.   

Abstract

This study investigated the effects of adrenomedullin on left ventricular myocardial contraction and relaxation, coronary blood flow, and myocardial oxygen consumption in comparison with those of atrial natriuretic peptide (ANP). Fourteen patients who had had myocardial infarctions were randomly assigned to receive IV infusion of adrenomedullin (0.05 microg/kg/min) or ANP (0.05 microg/kg/min). Both adrenomedullin and ANP significantly decreased left ventricular systolic pressure (-17 mm Hg, -13 mm Hg, respectively, both p < 0.05). The increase in cardiac index by adrenomedullin (+31%) was significantly greater than that by ANP (+16%). Adrenomedullin significantly increased an index of myocardial contractility, Emax (2.5 +/- 0.3 mm Hg-3.7 +/- 0.3 mm Hg/ml, p < 0.05) and shortened an index of myocardial relaxation, Tau (52 +/- 5 ms-48 +/- 4 ms, p < 0.05). In contrast, ANP did not significantly alter either parameter. In addition, adrenomedullin, but not ANP, significantly increased coronary sinus blood flow (73 +/- 10 ml/min-86 +/- 10 ml/min, p < 0.05). Adrenomedullin did not increase myocardial oxygen consumption. Unlike ANP, IV administration of adrenomedullin enhanced left ventricular myocardial contraction and improved left ventricular relaxation without increasing myocardial oxygen consumption in patients who had had a myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11973420     DOI: 10.1097/00005344-200205000-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.

Authors:  Mathilde Fraty; Gilberto Velho; Elise Gand; Fréderic Fumeron; Stéphanie Ragot; Philippe Sosner; Kamel Mohammedi; Barnabas Gellen; Pierre-Jean Saulnier; Jean-Michel Halimi; David Montaigne; Grégory Ducrocq; Michaela Rehman; Michel Marre; Ronan Roussel; Samy Hadjadj
Journal:  Diabetologia       Date:  2018-09-19       Impact factor: 10.122

Review 2.  [Role of adrenomedullin in the pathogenesis and treatment of cardiovascular dysfunctions and sepsis].

Authors:  M Westphal; J Sander; H Van Aken; C Ertmer; H D Stubbe; M Booke
Journal:  Anaesthesist       Date:  2006-02       Impact factor: 1.041

Review 3.  Adrenomedullin: Not Just Another Gastrointestinal Peptide.

Authors:  Sonia Martínez-Herrero; Alfredo Martínez
Journal:  Biomolecules       Date:  2022-01-18

4.  Precursor proadrenomedullin influences cardiomyocyte survival and local inflammation related to myocardial infarction.

Authors:  Svenja Hinrichs; Katharina Scherschel; Saskia Krüger; Johannes Tobias Neumann; Michael Schwarzl; Isabell Yan; Svenja Warnke; Francisco M Ojeda; Tanja Zeller; Mahir Karakas; Till Keller; Christian Meyer; Stefan Blankenberg; Dirk Westermann; Diana Lindner
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-30       Impact factor: 11.205

5.  Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide.

Authors:  R De Matteo; C N May
Journal:  Br J Pharmacol       Date:  2003-11-17       Impact factor: 8.739

6.  RNA SEQ Analysis Indicates that the AE3 Cl-/HCO3- Exchanger Contributes to Active Transport-Mediated CO2 Disposal in Heart.

Authors:  Kanimozhi Vairamani; Hong-Sheng Wang; Mario Medvedovic; John N Lorenz; Gary E Shull
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

Review 7.  Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.

Authors:  Toshihiro Kita; Kazuo Kitamura
Journal:  Hypertens Res       Date:  2022-01-06       Impact factor: 5.528

8.  MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy.

Authors:  Alexander C Falkentoft; Rasmus Rørth; Kasper Iversen; Dan E Høfsten; Henning Kelbæk; Lene Holmvang; Martin Frydland; Mikkel M Schoos; Steffen Helqvist; Anna Axelsson; Peter Clemmensen; Erik Jørgensen; Kari Saunamäki; Hans-Henrik Tilsted; Frants Pedersen; Christian Torp-Pedersen; Klaus F Kofoed; Jens P Goetze; Thomas Engstrøm; Lars Køber
Journal:  J Am Heart Assoc       Date:  2018-05-18       Impact factor: 5.501

Review 9.  Adrenomedullin Therapy in Moderate to Severe COVID-19.

Authors:  Toshihiro Kita; Kazuo Kitamura
Journal:  Biomedicines       Date:  2022-02-24

10.  Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101).

Authors:  Mahir Karakas; Dominik Jarczak; Martin Becker; Kevin Roedl; Marylyn M Addo; Frauke Hein; Andreas Bergmann; Jens Zimmermann; Tim-Philipp Simon; Gernot Marx; Marc Lütgehetmann; Axel Nierhaus; Stefan Kluge
Journal:  Biomolecules       Date:  2020-08-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.